Patents Assigned to Celldex Therapeutics, Inc.
-
Publication number: 20240360235Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.Type: ApplicationFiled: April 5, 2024Publication date: October 31, 2024Applicants: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.Inventors: Vladimir CORIC, Tibor KELER, Thomas DAVIS
-
Publication number: 20240287180Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).Type: ApplicationFiled: April 12, 2024Publication date: August 29, 2024Applicant: Celldex Therapeutics, Inc.Inventors: Theresa Marie LaVallee, Gerald McMahon
-
Patent number: 11987626Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).Type: GrantFiled: August 4, 2020Date of Patent: May 21, 2024Assignee: Celldex Therapeutics, Inc.Inventors: Theresa Marie LaVallee, Gerald McMahon
-
Publication number: 20240150493Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: December 18, 2023Publication date: May 9, 2024Applicant: Celldex Therapeutics, Inc.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 11965031Abstract: This invention provides methods for treating cancer in a subject comprising administering to the subject an anti-PD-1 antibody and an anti-CD27 antibody. In some embodiments, the cancer is colorectal cancer, rectal cancer, colon cancer, lung cancer, melanoma, ovarian cancer, head and neck cancer, or any combination thereof.Type: GrantFiled: November 16, 2020Date of Patent: April 23, 2024Assignees: Bristol-Myers Squibb Company, Celldex Therapeutics, Inc.Inventors: Vladimir Coric, Tibor Keler, Thomas Davis
-
Publication number: 20240117057Abstract: Provided herein are antibodies that immunospecifically bind to KIT, a receptor tyrosine kinase, and uses thereof. Also provided are polynucleotides and vectors encoding such antibodies, cells comprising such polynucleotides or vectors, and methods of making such antibodies.Type: ApplicationFiled: January 21, 2022Publication date: April 11, 2024Applicant: Celldex Therapeutics, Inc.Inventor: Joel Goldstein
-
Publication number: 20240109961Abstract: Provided herein are methods and uses of inhibitors of KIT, a receptor tyrosine kinase, for example, antibodies and antigen binding fragments that immunospecifically bind to KIT, for managing, treating, or preventing chronic prurigo, including prurigo nodularis (PN). Also provided are improved antibodies for use in such methods and uses.Type: ApplicationFiled: January 21, 2022Publication date: April 4, 2024Applicant: Celldex Therapeutics, Inc.Inventors: Bret Alan Holley, Joel Goldstein
-
Patent number: 11891452Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: GrantFiled: August 4, 2020Date of Patent: February 6, 2024Assignee: Celldex Therapeutics, Inc.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 11884734Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to MET, a receptor tyrosine kinase, and modulate the expression and/or activity of MET. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer. In one aspect, provided herein is a monoclonal antibody or antigen-binding fragment thereof that binds to the Sema/PSI domain of human MET. Also provided herein is a kit comprising an antibody or antigen-binding fragment provided herein. Also provided herein is a method of managing, protecting against, or treating cancer in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment provided herein.Type: GrantFiled: September 15, 2020Date of Patent: January 30, 2024Assignee: Celldex Therapeutics, Inc.Inventors: Yan Yang, Sreekala Mandiyan, Brett Robinson, Lida Kimmel, Yaron Hadari, Timothy David Jones, Francis Joseph Carr, Robert George Edward Holgate, Richard Weldon
-
Patent number: 11884699Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-mediated disorder or disease and methods of diagnosing a KIT-mediated disorder or disease using the antibodies described herein.Type: GrantFiled: August 14, 2020Date of Patent: January 30, 2024Assignee: Celldex Therapeutics, Inc.Inventors: Yaron Hadari, Elizabeth M. Mandel-Bausch, Susanne Radke, Joseph Schlessinger, Yoshihisa Suzuki
-
Patent number: 11541076Abstract: The invention provides chimeric antigen receptors (CARs) that specifically bind to the T-cell immunoglobulin and mucin domain 1 (TIM-1) protein. The invention further relates to modified immune cells, e.g., T or NK cells, comprising such CARs, CAR-encoding nucleic acids, CAR-encoding vectors, and methods of making such compositions. The invention further relates to methods for therapeutic use of these CARs and modified immune cells for the treatment of a condition, disorder, or disease associated with cells expressing TIM-1 (e.g., cancer).Type: GrantFiled: January 12, 2018Date of Patent: January 3, 2023Assignees: CELDARA MEDICAL, LLC, CELLDEX THERAPEUTICS, INC.Inventors: Terrance A. Stadheim, Joana M. Murad, Jake Reder, Henry C. Marsh, Jr., Li-Zhen He, Tibor Keler
-
Patent number: 11459393Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.Type: GrantFiled: April 17, 2019Date of Patent: October 4, 2022Assignee: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
-
Publication number: 20220177593Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to Axl, a receptor tyrosine kinase. Also provided are uses and methods for managing, treating, or preventing disorders, such as cancer using the anti-Axl antibodies.Type: ApplicationFiled: March 27, 2020Publication date: June 9, 2022Applicant: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Diego Alvarado, Richard W. Gedrich, Joel Goldstein, Laura Vitale, Thomas O'Neill, Andrea Crocker, Jenifer Widger, Michael B. Murphy, Shannon Pankratz
-
Patent number: 11332537Abstract: Provided herein are anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.Type: GrantFiled: August 18, 2021Date of Patent: May 17, 2022Assignee: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Joel Goldstein, Laura A. Vitale, Lizhen He
-
Publication number: 20220056127Abstract: Provided herein are methods and uses involving antibodies that specifically bind to a KIT receptor tyrosine kinase for managing, treating, or preventing an eosinophil or mast cell related disorder and/or one or more symptoms thereof, for example a mast cell related disorder of the nervous system, e.g., central nervous system, for example neuromyelitis optica (NMO), neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), and neurofibromatosis (NF).Type: ApplicationFiled: August 4, 2020Publication date: February 24, 2022Applicant: Celldex Therapeutics, Inc.Inventors: Theresa Marie LaVallee, Gerald McMahon
-
Publication number: 20220010027Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to a human KIT antigen comprising the fourth and/or fifth extracellular Ig-like domains (that is, D4 and/or D5 domains), polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. The antibodies can inhibit KIT activity, such as ligand-induced receptor phosphorylation. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to a KIT antigen, as well as methods of treating or managing a KIT-associated disorder or disease and methods of diagnosing a KIT-associated disorder or disease using the antibodies described herein.Type: ApplicationFiled: August 4, 2020Publication date: January 13, 2022Applicant: Celldex Therapeutics, Inc.Inventors: Yaron Hadari, Elizabeth M Mandel-Bausch, Francis Joseph Carr, Timothy David Jones, Laura Clare Alexandra Perry
-
Patent number: 11180566Abstract: Isolated monoclonal antibodies which bind to human CD27 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: GrantFiled: July 2, 2015Date of Patent: November 23, 2021Assignee: Celldex Therapeutics, Inc.Inventors: Tibor Keler, Henry C. Marsh, Lizhen He, Laura A. Vitale, Lawrence J. Thomas
-
Patent number: 11091559Abstract: Provided herein are compositions, methods and uses involving antibodies that specifically bind to ALK, a receptor tyrosine kinase, and modulate the expression and/or activity of ALK. Also provided are uses and methods for treating, e.g., managing, disorders, such as cancer.Type: GrantFiled: August 26, 2016Date of Patent: August 17, 2021Assignee: Celldex Therapeutics, Inc.Inventors: Diego Alvarado, Jay Lillquist, Gwenda Ligon, Michael Feldhaus
-
Publication number: 20210198374Abstract: Provided herein are novel anti-CD27 and anti-PD-L1 antibodies, and binding domains thereof, as well as bispecific constructs and anti-CD27 binding domain linked to an anti-PD-L1 binding domain. Also provided herein are methods of stimulating T cell activity, methods of inducing or enhancing an immune response, and methods of treating a disease or condition (e.g., cancer) by administering the bispecific constructs, antibodies, or antigen binding fragments thereof, or compositions described herein to a patient in need thereof.Type: ApplicationFiled: April 17, 2019Publication date: July 1, 2021Applicant: Celldex Therapeutics, Inc.Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE
-
Publication number: 20210147538Abstract: Isolated monoclonal agonistic antibodies which bind to human CD40 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.Type: ApplicationFiled: January 8, 2021Publication date: May 20, 2021Applicants: Celldex Therapeutics, Inc., Celldex Therapeutics, Inc.Inventors: Tibor KELER, Joel GOLDSTEIN, Laura A. VITALE, Lizhen HE, Tom O'NEILL, Andrea CROCKER, Karuna SUNDARAPANDIYAN, Lawrence J. THOMAS, Jenifer WIDGER